Subscribe for Free (RSS + E-mail)

RSS + E-mail

Incubator Guide →
Featured▾
- XSITE 2013 →
Xconomy National
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

carnst

Catherine Arnst

Catherine Arnst is an award- winning writer and editor specializing in science and medicine. Catherine was Senior Writer for medicine at BusinessWeek for 13 years, where she wrote numerous cover stories and wrote extensively for the magazine’s website, including contributing to two blogs. She followed a broad range of issues affecting medicine and health and held primary responsibility for covering the battle in Washington over health care reform. Catherine has also written for the Boston Globe, U.S. News & World Report and The Daily Beast, and was Director of Content Development for the health practice at Edelman Public Relations for two years. Prior to joining BusinessWeek she was the London-based European Science Correspondent for Reuters News Service. She won the 2004 Business Journalist of the Year award from London’s World Leadership Forum, and in 2003 was the first recipient of the ACE Reporter Award from the European School of Oncology for her five-year body of work on cancer. She holds a bachelor’s degree in journalism from Boston University.

Recent posts

Onyx, Millennium, Ariad: Firms to Watch at Hematology Meeting

[Corrected 12/07/12, 10:18 pm. See below.] The life sciences industry has been talking up personalized medicine for more than a decade, but so far the idea that diseases will... Read more »
Flexion Therapeutics Secures $20 Million to Fight Osteoarthritis

[Corrected 12/04/12, 9:08 a.m. See below.] Flexion Therapeutics, based in Woburn, MA, said today that it has raised $20 million in a Series B financing led by Novo... Read more »
1stdibs Raises $42 Million in Series B Round

[Updated 12/03/12 5:55 pm. See below.]When it comes to online shopping, you can’t get more high-end than 1stdibs, an 11-year-old online retailer based in New York that trades... Read more »
Fashion Sites Nomorerack, Rent the Runway Raise Funds

Christmas is coming early for two web-based fashion startups in New York, often referred to as the Target and the Netflix of online shopping. Nomorerack, the Target counterpart, is a... Read more »
East Coast Life Sciences Roundup: Selecta, Rib-X, Cambridge, & More

Big Pharma expanded its love affair with biotech startups this week, making investments and doing deals, while Cambridge continued to be the place to do business for emerging life sciences companies.... Read more »
Rib-X Closes First Tranche of $67.5 Million Preferred Stock Financing

[Updated 11:21 a.m.] Rib-X Pharmaceuticals of New Haven, CT, said today that it closed the first tranche of a $67.5 million Series 2 preferred stock financing, with a second... Read more »
Nick Beim Jumps from Matrix Partners to Venrock

Boston-based venture capital firm Matrix Partners has lost its New York-based partner. Star investor Nick Beim, who had been with Matrix for 12 years and in New York for the firm... Read more »
Selecta in Development Deal with Sanofi Worth up to $900 Million

[Updated 11/28/12, 11:04 a.m.]Selecta Biosciences, one of the many startups to emerge from the lab of famed MIT bioengineer Robert Langer, reported today that it scored... Read more »
Pfizer Invests in Rhythm to Support Diabetes, Obesity Drug Programs

Boston-based Rhythm can move ahead with its experimental drugs for obesity and diabetes assured of a very deep-pocketed partner. The startup announced today that Pfizer Venture Investments, the venture capital... Read more »
Coridea Out to Prove Devices can Replace Drugs—and Succeeding

The burning question of the biopharma industry over the last several years is “where are the new drugs?” With blockbusters going off patent and investigational drugs failing in clinical trial after... Read more »
Hello Health Raises $11.5 Million to Expand Electronic Health Records

Hello Health, which has an unusual model for offering electronic health records systems to doctors, said today that it raised $11.5 million in additional financing, with First Generation Capital as... Read more »
East Coast Life Sciences Roundup: Insider Trading, Shire, Pfizer

Alleged skullduggery by some New Jersey pharma execs, drug development pacts, and a European drug approval marked this holiday week on the East Coast.

—The holiday-shortened week started out with an... Read more »
Investors Interested in Health IT—With Caveats

Established companies such as Dell Computer (NASDAQ: DELL) and Becton Dickinson (NYSE: BDX) say they are eager to invest in health IT startups—they just need to figure out how... Read more »
Celgene, Sanofi, Stryker Execs Charged With Insider Trading

Three high-powered New Jersey pharmaceutical executives from Celgene (NASDAQ: CELG), Sanofi (NYSE: SNY), and Stryker (NYSE: SYK) were charged today with insider trading by the U.S. Securities and... Read more »
Pfizer, Cystic Fibrosis Foundation in $58 Million Pact

The Cystic Fibrosis Foundation says it has agreed to invest up to $58 million over six years to expand its drug development partnership with New York-based Pfizer (NYSE: PFE), in... Read more »
MoMelan Technologies Stealthily Acquired by Kinetic Concepts

MoMelan Technologies, a three-year-old Cambridge, MA, startup with an unusual skin graft technology invented by laser hair removal pioneer R. Rox Anderson, was secretly acquired by San Antonio, TX-based Kinetic... Read more »
East Coast Life Sciences Roundup: Bristol-Myers, Alnylam, Merck, & More

The East Coast produced some good news this week about treatments for hepatitis C, some big deals, and at long last, hope for victims of bedbugs.

—Advances against deadly hepatitis C... Read more »
Worldwide Investor Network Pairs Foreign Startups, NY Money

There are some 300 incubators outside the U.S. nurturing hundreds of innovative startup companies, according to Eyal Bino, founder of Worldwide Investor Network. But few of these enterprises attract the... Read more »
Forest Labs, Adamas in Pact to Develop Alzheimer’s Drug Combo

In a play to extend the life of its top-selling Alzheimer’s drug memantine (Namenda XR) beyond its patent expiration, New York-based Forest Laboratories (NYSE: FRX) agreed to pay Adamas Pharmaceuticals... Read more »
Hepatitis C Treatments from Gilead, Abbott Wow Liver Meeting

This weekend demonstrated what a difference a year makes for Cambridge, MA-based Vertex (NASDAQ: VRTX). At the annual meeting of the American Associaton for the Study of Liver Diseases in... Read more »

Page 3 of 5 « previous page · next page »